Gyre Therapeutics Inc (GYRE)
Gyre Therapeutics Inc. is a NASDAQ-listed common stock company in the healthcare sector and biotechnology industry. The San Diego-based pharmaceutical company focuses on developing and commercializing small-molecule therapies with anti-inflammatory and anti-fibrotic activity for organ fibrosis. Its marketed product includes ETUARY (pirfenidone), an approved treatment for idiopathic pulmonary fibrosis, which is also being studied in Phase 3 trials for pneumoconiosis. Gyre is also advancing F351 (hydronidone), a structural derivative of ETUARY, in Phase 3 trials for chronic hepatitis B-related liver fibrosis and has completed Phase 1 testing in liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. Additional pipeline candidates include F573, in Phase 2 trials for acute and acute-on-chronic liver failure, as well as preclinical programs F230 for pulmonary arterial hypertension and F528 for chronic obstructive pulmonary disease. Founded in 2002, the company operates as a subsidiary of GNI USA, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GYRE
|
$5.62
|
-7.0% Downside
|
Fair
|
$18.67
|
209.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-105.9x
|
6.7x
|
5.8x
|
655.6 M
|
629.5 M
|
0.1%
|
37.1%
|
16.4
|
—
|
-48.3%
|
